Skip to main content

IMDx Assays for Abbott Platform Gain Licensure in Canada, Singapore

NEW YORK (GenomeWeb) — IMDx said today that it has received three additional licenses for sale and distribution of its molecular tests for the Abbott m2000 platform outside the US and EU.

First, the IMDx C. difficile assay for the qualitative detection of toxigenic Clostridium difficile toxin A and B genes, and the Flu A/B and RSV assay for the qualitative detection of influenza A, influenza B, and respiratory syncytial virus have been approved by Health Canada for sale and distribution in Canada.

In addition, the IMDx C. difficile assay has been approved by the Health Sciences Authority for sale and distribution in Singapore, IMDx said.

These tests join the previously licensed IMDx VanR for Abbott m2000 assay in the company's portfolio of tests commercially available in Canada and Singapore.

IMDx, based in Waltham, Mass., has been developing real-time tests for the Abbott m2000 testing system under a multi-year agreement signed between the companies in 2011.

Several such tests have already been CE marked or approved by the US Food and Drug Administration, and IMDx said this week that it has been placing "significant focus" on obtaining international licenses to globally distribute and sell these products.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.